GlaxoSmithKline (GSK) and the Singapore Economic Development Board (EDB) will financially support eight research projects based in Singapore focused on green and sustainable manufacturing. The partnership will be funded by the GSK-EDB $35 million joint fund over 10 years to grow Singapore’s local capabilities and talent.
The first round of programs will receive about $3.5 million under the $24 million GSK-Singapore Partnership for Green & Sustainable Manufacturing. Eight principal investigators from the Institute of Chemical and Engineering Sciences, Nanyang Technological University, and the National University of Singapore have received awards. They will concentrate on chemical-, physical- and bio-transformations to maximize resource efficiency and minimize waste generated during the manufacturing process.
The joint fund is part of GSK-Singapore 10-year Strategic Roadmap to address the industry’s challenges and co-create innovative solutions. “The funds we are committing for the research on green and sustainable manufacturing over 10 years will help Singapore to become a leader in sustainability research in pharmaceuticals and fine chemicals manufacturing and ensure that companies such as GSK can improve the efficiency of all activities by minimizing materials, energy, and waste worldwide,” says Andrew Witty, CEO of GSK.